# Distribution of Sentinel Nodes in Non‐Parotid Salivary Gland Tumors—A Feasibility Study

**Authors:** Marcus Jansson, Rusana Bark, Alexandra Elliot, Lalle Hammarstedt‐Nordenvall, Caroline Gahm

PMC · DOI: 10.1002/cnr2.70510 · 2026-03-06

## TL;DR

This study shows that sentinel node mapping is feasible in non-parotid salivary gland tumors, potentially improving cancer staging and treatment decisions.

## Contribution

The study demonstrates the feasibility of sentinel node detection in non-parotid salivary gland tumors using SPECT–CT imaging.

## Key findings

- Sentinel nodes were detected in 85% of patients with non-parotid salivary gland tumors.
- Micrometastases were found in sentinel lymph nodes of five patients with aggressive malignancies.
- Bilateral sentinel node distribution was observed in minor salivary gland tumors but not in submandibular tumors.

## Abstract

Salivary gland carcinomas are rare and heterogeneous malignancies, more common in the parotid gland but also in submandibular and minor salivary glands. Surgery, often combined with radiotherapy, is the main treatment. Management of the clinically node‐negative (cN0) neck is debated, with some favoring extensive surgery and others active surveillance. The sentinel node (SN) technique may improve nodal staging and personalized surgery but is understudied in non‐parotid tumors.

This study aimed to evaluate whether the technique is applicable to assess SN distribution in these patients.

In this prospective observational feasibility study, 40 patients with cytologically suspected benign or malignant non‐parotid salivary gland tumors were enrolled. Preoperatively, patients received an ultrasound‐guided intratumoral injection of Tc‐99m‐labeled tracer, followed by SPECT–CT imaging for SN localization. Intraoperatively, SNs were detected using a gamma probe, and sentinel lymph node biopsy (SLNB) was performed when indicated. SNs were detected in 33 of 39 (85%) patients. Bilateral distribution of SNs was seen in two of 12 patients with minor salivary gland tumors but in none with submandibular tumors (n = 27). One patient was excluded due to a non‐salivary gland diagnosis. SLNB was performed in 16 patients with cytology indicating aggressive malignancies in which micrometastases were detected in three patients with submandibular gland tumors and in two patients with minor salivary gland tumors.

SN mapping was feasible in patients with non‐parotid salivary gland tumors, with a high detection rate using SPECT–CT. SN distribution was primarily ipsilateral but bilateral in two patients with minor salivary gland tumors. Identification of SN micrometastases highlights the potential of SLNB to improve staging accuracy. Our findings support further investigation of the SN technique as a diagnostic tool in the management of cN0 neck in this rare tumor group.

## Full-text entities

- **Diseases:** malignant melanoma (MESH:D008545), adenoid cystic carcinoma (MESH:D003528), SN (MESH:D012804), nodal disease (MESH:D004194), adenocarcinoma (MESH:D000230), benign (MESH:D009369), Head and Neck Cancer (MESH:D006258), oral cancer (MESH:D009062), Parotid Salivary Gland Tumors (MESH:C563951), gland (MESH:D000307), mucoepidermoid carcinoma (MESH:D018277), squamous cell carcinoma (MESH:D002294), Submandibular Gland Tumors (MESH:D013365), Salivary Gland Tumors (MESH:D012468), oral squamous cell carcinoma (MESH:D000077195), metastases (MESH:D009362), micrometastasis (MESH:D061206), nodal (MESH:D013611), SN metastases (MESH:D008207), breast cancer (MESH:D001943), pleomorphic adenoma (MESH:D008949), parotid tumors (MESH:D010307), salivary duct carcinoma (MESH:D012465)
- **Chemicals:** Tc-99m (MESH:D013667), Nanocolloid (-), ICG (MESH:D007208), formalin (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966343/full.md

---
Source: https://tomesphere.com/paper/PMC12966343